Moderna (MRNA) Tops Q4 EPS by $1.54, Beats on Revenue, Reaffirms COVID-19 Vax Guidance
Moderna (NASDAQ: MRNA) reported Q4 EPS of $0.55, $1.54 better than the analyst estimate of ($0.99). Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.51 billion.
The Company is reaffirming its 2024 product sales outlook as it enters the second year of the U.S. commercial endemic COVID market with increased clarity of market size and dynamics. Moderna continues to focus on public health efforts to increase vaccination coverage rates globally for the 2024/2025 season to reduce the substantial burden of COVID-19. The Company is also prioritizing key international markets for greater commercial focus and is participating in the EU Health Emergency and Response Authority's tendering procedure for up to 36 million doses of mRNA COVID-19 vaccines per year for up to four years.
For earnings history and earnings-related data on Moderna (MRNA) click here.